Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

A single untimed plasma drug concentration measurement during low-level HIV viremia predicts virologic failure.

Gonzalez-Serna A, Swenson LC, Watson B, Zhang W, Nohpal A, Auyeung K, Montaner JS, Harrigan PR.

Clin Microbiol Infect. 2016 Dec;22(12):1004.e9-1004.e16. doi: 10.1016/j.cmi.2016.08.012. Epub 2016 Aug 30.

2.

Risk of breast cancer with CXCR4-using HIV defined by V3 loop sequencing.

Goedert JJ, Swenson LC, Napolitano LA, Haddad M, Anastos K, Minkoff H, Young M, Levine A, Adeyemi O, Seaberg EC, Aouizerat B, Rabkin CS, Harrigan PR, Hessol NA.

J Acquir Immune Defic Syndr. 2015 Jan 1;68(1):30-5. doi: 10.1097/QAI.0000000000000400.

3.

"Deep" sequencing accuracy and reproducibility using Roche/454 technology for inferring co-receptor usage in HIV-1.

Knapp DJ, McGovern RA, Poon AF, Zhong X, Chan D, Swenson LC, Dong W, Harrigan PR.

PLoS One. 2014 Jun 24;9(6):e99508. doi: 10.1371/journal.pone.0099508. eCollection 2014.

4.

Theoretical and experimental assessment of degenerate primer tagging in ultra-deep applications of next-generation sequencing.

Liang RH, Mo T, Dong W, Lee GQ, Swenson LC, McCloskey RM, Woods CK, Brumme CJ, Ho CK, Schinkel J, Joy JB, Harrigan PR, Poon AF.

Nucleic Acids Res. 2014 Jul;42(12):e98. doi: 10.1093/nar/gku355. Epub 2014 May 7.

5.

Comparative performances of HIV-1 RNA load assays at low viral load levels: results of an international collaboration.

Swenson LC, Cobb B, Geretti AM, Harrigan PR, Poljak M, Seguin-Devaux C, Verhofstede C, Wirden M, Amendola A, Boni J, Bourlet T, Huder JB, Karasi JC, Zidovec Lepej S, Lunar MM, Mukabayire O, Schuurman R, Tomazic J, Van Laethem K, Vandekerckhove L, Wensing AM; International Viral Load Assay Collaboration.

J Clin Microbiol. 2014 Feb;52(2):517-23. doi: 10.1128/JCM.02461-13. Epub 2013 Dec 4.

6.

HIV drug resistance detected during low-level viraemia is associated with subsequent virologic failure.

Swenson LC, Min JE, Woods CK, Cai E, Li JZ, Montaner JS, Harrigan PR, Gonzalez-Serna A.

AIDS. 2014 May 15;28(8):1125-34. doi: 10.1097/QAD.0000000000000203.

7.

Performance of HIV-1 drug resistance testing at low-level viremia and its ability to predict future virologic outcomes and viral evolution in treatment-naive individuals.

Gonzalez-Serna A, Min JE, Woods C, Chan D, Lima VD, Montaner JS, Harrigan PR, Swenson LC.

Clin Infect Dis. 2014 Apr;58(8):1165-73. doi: 10.1093/cid/ciu019. Epub 2014 Jan 14.

8.

Reply to "Issues on results of the external quality assessment for proviral DNA testing of HIV-1 Tropism in the Maraviroc Switch collaborative study".

Tu E, Swenson LC, Land S, Pett S, Emery S, Marks K, Kelleher AD, Kaye S, Kaiser R, Schuelter E, Harrigan R; MARCH Laboratory Group and the MARCH Study Group.

J Clin Microbiol. 2013 Dec;51(12):4287. doi: 10.1128/JCM.02207-13. No abstract available.

9.

Genotypic analysis of the V3 region of HIV from virologic nonresponders to maraviroc-containing regimens reveals distinct patterns of failure.

Swenson LC, Chui CK, Brumme CJ, Chan D, Woods CK, Mo T, Dong W, Chapman D, Lewis M, Demarest JF, James I, Portsmouth S, Goodrich J, Heera J, Valdez H, Harrigan PR.

Antimicrob Agents Chemother. 2013 Dec;57(12):6122-30. doi: 10.1128/AAC.01534-13. Epub 2013 Sep 30.

10.

Results of external quality assessment for proviral DNA testing of HIV tropism in the Maraviroc Switch collaborative study.

Tu E, Swenson LC, Land S, Pett S, Emery S, Marks K, Kelleher AD, Kaye S, Kaiser R, Schuelter E, Harrigan R; MARCH Laboratory Group and the MARCH Study Group.

J Clin Microbiol. 2013 Jul;51(7):2063-71. doi: 10.1128/JCM.00510-13. Epub 2013 Apr 17.

11.

Use of cellular HIV DNA to predict virologic response to maraviroc: performance of population-based and deep sequencing.

Swenson LC, Dong WW, Mo T, Demarest J, Chapman D, Ellery S, Heera J, Valdez H, Poon AF, Harrigan PR.

Clin Infect Dis. 2013 Jun;56(11):1659-66. doi: 10.1093/cid/cit105. Epub 2013 Feb 21.

PMID:
23429552
12.

Development of a novel codon-specific polymerase chain reaction for the detection of CXCR4-utilizing HIV type 1 subtype B.

McLaughlin S, Swenson LC, Hu S, Hughes P, Harrigan PR, Coombs RW, Frenkel LM.

AIDS Res Hum Retroviruses. 2013 May;29(5):814-25. doi: 10.1089/AID.2012.0024. Epub 2013 Mar 6.

13.

Factors influencing the sensitivity and specificity of conventional sequencing in human immunodeficiency virus type 1 tropism testing.

Knapp DJ, McGovern RA, Dong W, Poon AF, Swenson LC, Zhong X, Woods CK, Harrigan PR.

J Clin Microbiol. 2013 Feb;51(2):444-51. doi: 10.1128/JCM.00739-12. Epub 2012 Nov 21.

14.

Reconstructing the dynamics of HIV evolution within hosts from serial deep sequence data.

Poon AF, Swenson LC, Bunnik EM, Edo-Matas D, Schuitemaker H, van 't Wout AB, Harrigan PR.

PLoS Comput Biol. 2012;8(11):e1002753. doi: 10.1371/journal.pcbi.1002753. Epub 2012 Nov 1.

15.

Prolonged and substantial discordance in prevalence of raltegravir-resistant HIV-1 in plasma versus PBMC samples revealed by 454 "deep" sequencing.

Lee GQ, Swenson LC, Poon AF, Martin JN, Hatano H, Deeks SG, Harrigan PR.

PLoS One. 2012;7(9):e46181. doi: 10.1371/journal.pone.0046181. Epub 2012 Sep 26.

16.

Technical and regulatory shortcomings of the TaqMan version 1 HIV viral load assay.

Brumme CJ, Swenson LC, Wynhoven B, Yip B, Skinner S, Lima VD, Montaner JS, Harrigan PR.

PLoS One. 2012;7(8):e43882. doi: 10.1371/journal.pone.0043882. Epub 2012 Aug 24.

17.

Next-generation sequencing to assess HIV tropism.

Swenson LC, Däumer M, Paredes R.

Curr Opin HIV AIDS. 2012 Sep;7(5):478-85. doi: 10.1097/COH.0b013e328356e9da. Review.

PMID:
22832710
18.

Deep V3 sequencing for HIV type 1 tropism in treatment-naive patients: a reanalysis of the MERIT trial of maraviroc.

Swenson LC, Mo T, Dong WW, Zhong X, Woods CK, Thielen A, Jensen MA, Knapp DJ, Chapman D, Portsmouth S, Lewis M, James I, Heera J, Valdez H, Harrigan PR.

Clin Infect Dis. 2011 Oct;53(7):732-42. doi: 10.1093/cid/cir493.

PMID:
21890778
19.

Detection of inferred CCR5- and CXCR4-using HIV-1 variants and evolutionary intermediates using ultra-deep pyrosequencing.

Bunnik EM, Swenson LC, Edo-Matas D, Huang W, Dong W, Frantzell A, Petropoulos CJ, Coakley E, Schuitemaker H, Harrigan PR, van 't Wout AB.

PLoS Pathog. 2011 Jun;7(6):e1002106. doi: 10.1371/journal.ppat.1002106. Epub 2011 Jun 23.

20.

Mutations in gp41 are correlated with coreceptor tropism but do not improve prediction methods substantially.

Thielen A, Lengauer T, Swenson LC, Dong WW, McGovern RA, Lewis M, James I, Heera J, Valdez H, Harrigan PR.

Antivir Ther. 2011;16(3):319-28. doi: 10.3851/IMP1769.

PMID:
21555814
21.

"Dynamic range" of inferred phenotypic HIV drug resistance values in clinical practice.

Swenson LC, Pollock G, Wynhoven B, Mo T, Dong W, Hogg RS, Montaner JS, Harrigan PR.

PLoS One. 2011 Feb 24;6(2):e17402. doi: 10.1371/journal.pone.0017402.

22.

Deep sequencing to infer HIV-1 co-receptor usage: application to three clinical trials of maraviroc in treatment-experienced patients.

Swenson LC, Mo T, Dong WW, Zhong X, Woods CK, Jensen MA, Thielen A, Chapman D, Lewis M, James I, Heera J, Valdez H, Harrigan PR.

J Infect Dis. 2011 Jan 15;203(2):237-45. doi: 10.1093/infdis/jiq030.

23.

Genotypic inference of HIV-1 tropism using population-based sequencing of V3.

McGovern RA, Harrigan PR, Swenson LC.

J Vis Exp. 2010 Dec 27;(46). pii: 2531. doi: 10.3791/2531.

24.

Improved detection of CXCR4-using HIV by V3 genotyping: application of population-based and "deep" sequencing to plasma RNA and proviral DNA.

Swenson LC, Moores A, Low AJ, Thielen A, Dong W, Woods C, Jensen MA, Wynhoven B, Chan D, Glascock C, Harrigan PR.

J Acquir Immune Defic Syndr. 2010 Aug;54(5):506-10. doi: 10.1097/QAI.0b013e3181d0558f.

PMID:
20512044
25.

Phylogenetic analysis of population-based and deep sequencing data to identify coevolving sites in the nef gene of HIV-1.

Poon AF, Swenson LC, Dong WW, Deng W, Kosakovsky Pond SL, Brumme ZL, Mullins JI, Richman DD, Harrigan PR, Frost SD.

Mol Biol Evol. 2010 Apr;27(4):819-32. doi: 10.1093/molbev/msp289. Epub 2009 Dec 2.

26.

HLA-associated immune escape pathways in HIV-1 subtype B Gag, Pol and Nef proteins.

Brumme ZL, John M, Carlson JM, Brumme CJ, Chan D, Brockman MA, Swenson LC, Tao I, Szeto S, Rosato P, Sela J, Kadie CM, Frahm N, Brander C, Haas DW, Riddler SA, Haubrich R, Walker BD, Harrigan PR, Heckerman D, Mallal S.

PLoS One. 2009 Aug 19;4(8):e6687. doi: 10.1371/journal.pone.0006687.

27.

HIV coreceptor phenotyping in the clinical setting.

Low AJ, Swenson LC, Harrigan PR.

AIDS Rev. 2008 Jul-Sep;10(3):143-51. Review.

PMID:
18820716
28.
29.

Lumbar epidural lipomatosis: the "Y" sign of thecal sac compression.

Kuhn MJ, Youssef HT, Swan TL, Swenson LC.

Comput Med Imaging Graph. 1994 Sep-Oct;18(5):367-72.

PMID:
7954313
30.

Monoclonal antibodies in ovarian and prostate cancer.

Neal CE, Swenson LC, Fanning J, Texter JH.

Semin Nucl Med. 1993 Apr;23(2):114-26. Review.

PMID:
8511599
31.

Absence of the septum pellucidum and related disorders.

Kuhn MJ, Swenson LC, Youssef HT.

Comput Med Imaging Graph. 1993 Mar-Apr;17(2):137-47.

PMID:
8518995
32.

Learning of a single alternation concept under conditions of cortical spreading depression in rats.

Swenson LC, Catania JJ.

Physiol Behav. 1973 Sep;11(3):319-22. No abstract available.

PMID:
4745053
33.

One versus two discrimination by whitenecked ravens (Corvus cryptoleucus) with non-number dimensions varied.

Swenson LC.

Anim Behav. 1970 Aug;18(3):454-60. No abstract available.

PMID:
5498032

Supplemental Content

Loading ...
Support Center